IGC Pharma (NYSEAMERICAN:IGC) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of IGC Pharma (NYSEAMERICAN:IGC) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the construction company’s stock.

IGC Pharma Stock Performance

Shares of IGC opened at $0.51 on Tuesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.85 and a quick ratio of 0.86. IGC Pharma has a twelve month low of $0.25 and a twelve month high of $0.91. The company has a market capitalization of $33.94 million, a price-to-earnings ratio of -1.95 and a beta of 1.71.

IGC Pharma (NYSEAMERICAN:IGC) last posted its quarterly earnings data on Wednesday, February 14th. The construction company reported ($0.09) earnings per share (EPS) for the quarter. The company had revenue of $0.20 million for the quarter. IGC Pharma had a negative net margin of 1,163.24% and a negative return on equity of 110.37%.

Institutional Inflows and Outflows

An institutional investor recently raised its position in IGC Pharma stock. Commonwealth Equity Services LLC raised its stake in shares of IGC Pharma, Inc. (NYSEAMERICAN:IGC) by 211.3% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 165,490 shares of the construction company’s stock after buying an additional 112,334 shares during the period. Commonwealth Equity Services LLC owned about 0.31% of IGC Pharma worth $59,000 at the end of the most recent quarter. Institutional investors and hedge funds own 3.87% of the company’s stock.

About IGC Pharma

IGC Pharma, Inc, a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development.